



P1196 ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical

Chang-Ju Qu*1, Hai-Ling Liu², Rui Zou¹, Na-Na Ping¹, Qian Zhu¹, Xiao Zhang¹, Jia-Jie He¹, De-Pei Wu¹, Zheng-Ming Jin¹

¹Department Of Hematology, The First Affiliated Hospital Of Soochow University, Suzhou, China; ²Department Of Radiology, people's Hospital Of Binhai County, Yancheng, China

Background:

The prognosis of patients (pts) with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) is poor. Bruton tyrosine kinase inhibitors (BTKi) have shown therapeutic activity in non-GCB DLBCL. Orelabrutinib (O), as a novel covalent BTKi with high target selection, was reported to preserve the NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC) induced by rituximab (R) and thus boosted the antitumor effect of R-based regimen.

Aims:

This study aimed to analyze the efficacy and safety of O plus R-CHOP-like (O+R-CHOP) for previously untreated non-GCB DLBCL pts who benefited from induction therapy of O plus R (OR).

Methods:

Pts with histopathologically confirmed newly diagnosed non-GCB DLBCL have enrolled in this ongoing, prospective, multicenter, open-label phase II study (NCT05498259). Pts received O (150 mg, once daily [qd]) and R (375 mg/m2, day 1) as induction therapy for 21 days. Then, pts with a reduction in a lesion of ≥25% received O (150 mg, qd) and R-CHOP as combination therapy on a 21-day cycle for 6 cycles. The primary endpoint was the complete remission rate (CRR) after 6 cycles of O+R-CHOP. Secondary endpoints were mini or better response rate (mRR, defined as the percentage of pts with complete remission [CR], partial remission [PR], and mini response [miniR, lesion reduction: 25.0%-50.0%]) after OR, Overall response rate (ORR) and progression-free survival (PFS) after O+R-CHOP, and safety profiles.

Results:

Ten pts were enrolled by the cutoff date (February 10, 2023). The median age was 61.5 (range 27-68) years. All had stage III-IV disease, extranodal involvement (70.0%), and MYC/BCL2 double expression lymphoma (DEL, 60.0%). Next-generation sequencing was performed in 9 (90.0%) pts to detect genetic mutations, including MYD88 (n=4, 44.4%), CD79A (n=2, 22.2%), and TP53 (n=1, 11.1%) mutations.

All 10 pts completed induction therapy, 9 pts attained a response, and the mRR was 90.0% (CR=40.0%, PR=40.0%, miniR=10.0%) and then 9 pts continued to receive O+R-CHOP. Six (66.7%) pts completed ≥3 cycles of O+R-CHOP and all achieved CR at the end of cycle 3; among whom 1 (11.1%) maintained CR at the end of cycle 6 (Figure 1). During the whole treatment, 8 (88.9%) of 9 pts had CR as their best response, with an ORR and CRR of 88.9%. No progressive disease or death was reported. By the subgroup analysis of 10 pts at the induction stage, pts with DEL had better mRR (100.0% vs. 66.7%) than that non-DEL. A similar result was observed in pts with extranodal involvement over those without (mRR, 100.0% vs. 66.7%). In 9 pts who received O+R-CHOP, pts with DEL and extranodal involvement achieved CRR of 100.0% and 85.7%, respectively. Pts with MYD88 (n=4) and CD79A (n=2) mutations obtained CR.

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.


HemaSphere



At the induction stage, 4 (40.0%) pts experienced adverse events (AEs), with grade 1-2 hematological AEs. During the whole treatment, AEs occurred in 8 (80.0%) pts, and the common AEs were lymphocyte count decreased (60.0%) and white blood cell decreased (50.0%). Grade \geq 3 AEs occurred in 3 (30.0%) pts, including lymphocyte count decreased (10.0%), pulmonary infection (10.0%), and white blood cell decreased (10.0%). As data cutoff, 8 (88.9%) were still under treatment.

Summary/Conclusion:

Although preliminary, the responders to the OR induction therapy may attain a synergistic antitumor effect and thus achieve a high CRR when receiving subsequent O+R-CHOP. The safety was favorable. More updated data will be presented from this ongoing study.



Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.